Siga Technologies INC 8-K filings

SIGA Technologies announced its first-quarter 2026 financial results, highlighting planned deliveries of TPOXX to international and U.S. government customers, alongside a new international license agreement.

SIGA Technologies announced its financial results for the first nine months of 2025, showing significant revenue and income growth year-to-date, despite a notable decline in Q3 2025 compared to the prior year.

SIGA Technologies reported robust financial results for Q2 2025, driven by significant TPOXX product sales and new BARDA development funding.

SIGA Technologies, Inc. announced the amendment of its bylaws to establish exclusive forum provisions for legal claims and reported the successful election of all director nominees and ratification of its independent auditor at its 2025 Annual Meeting of Stockholders.

SIGA Technologies announces its financial results for the three months ended March 31, 2025, including a $26 million IV TPOXX procurement order from the U.S. Government.

SIGA Technologies declares a special one-time cash dividend of $0.60 per share, payable on May 15, 2025, to shareholders of record as of April 29, 2025.

SIGA Technologies appoints General John M. Jack Keane (Ret.) to its Board of Directors, effective immediately.

SIGA Technologies announces positive financial results for 2024, highlighted by increased product sales and significant pre-tax operating income.

SIGA Technologies has amended its bylaws to update procedures for stockholder nominations and proposals, reflecting recent SEC rule changes and Delaware law updates.

An interim analysis of the STOMP study revealed that SIGA Technologies' tecovirimat did not improve time to lesion resolution compared to placebo in adults with mild to moderate mpox, leading to the study halting enrollment.

SIGA Technologies announced robust financial results for the third quarter of 2024, highlighted by $122 million in procurement orders from the U.S. government.

SIGA Technologies has amended the employment agreements of its CFO and CSO to shift their compensation towards long-term equity incentives.

SIGA Technologies has terminated its Executive Vice President and Chief Medical Officer, Dr. Jay Varma, effective immediately, which also resulted in the end of his service on the company's Board of Directors.

SIGA Technologies' Executive Vice President and Chief Medical Officer, Dr. Jay K. Varma, has commenced an indefinite leave of absence from his executive and board positions, effective September 19, 2024.

A clinical trial of SIGA Technologies' tecovirimat for mpox treatment did not meet its primary endpoint, but showed potential benefit in patients treated early and those with severe disease.

SIGA Technologies announced strong financial results for the second quarter of 2024, highlighted by $21 million in product sales and a significant $113 million procurement order from the U.S. Government.

SIGA Technologies has received a $113 million procurement order from the U.S. government for its oral TPOXX treatment, enhancing orthopoxvirus preparedness.

SIGA Technologies held its 2024 Annual Meeting where stockholders elected nine directors and ratified the appointment of PricewaterhouseCoopers LLP as the company's independent auditor.

SIGA Technologies announced robust first-quarter 2024 financial results, highlighted by $24 million in product sales and $11 million in pre-tax operating income.

SIGA Technologies will assume primary responsibility for the advertising, promotion, and sale of oral TPOXX globally, with Meridian Medical Technologies retaining limited rights in specific regions.

SIGA Technologies reported a significant increase in product sales and pre-tax operating income for 2023, and declared a special cash dividend of $0.60 per share.

SIGA Technologies has appointed Diem Nguyen as its new CEO, effective January 27, 2024, to lead the company's global health security initiatives.